Key Takeaways
- • Vermont has enacted a new law increasing regulatory scrutiny of private equity and hedge fund investments in health care organizations, reflecting a broader nationwide trend of state-level restrictions on alternative investment involvement in clinical operations.
- • Christina Bergeron, a health care partner at Ropes & Gray, advises PE and hedge fund investors to audit their existing health care investments to ensure they are not influencing clinical operations and to document compliance with the new requirements.
- • The Vermont law does not categorically restrict PE firms or hedge funds from investing in health care, but instead imposes conditions on how such investors can structure their ownership and operational involvement.
- • This regulatory development mirrors enforcement actions in other states; California and Oregon have begun enforcing corporate-medicine restrictions, with California's Attorney General securing a $2.3 million settlement against Aspen Dental Management for violations.
Summary
Vermont has enacted legislation that substantially increases oversight of private equity and hedge fund investments in health care entities, marking a significant shift in state-level regulatory approach to alternative asset ownership in the sector. According to Christina Bergeron, a partner at Ropes & Gray specializing in health care matters, this development reflects an acceleration of a nationwide trend toward state-level scrutiny of private investment in health care organizations.
The Vermont law, referenced as H.583, does not impose an outright prohibition on PE or hedge fund participation in health care investments. Instead, it establishes conditions and transparency requirements governing how such investors can structure their ownership stakes and operational involvement. Bergeron emphasized that the statute focuses on preventing investor influence over clinical operations—the core concern driving broader state legislative action in this area.
For alternative investment managers currently holding health care positions, Bergeron outlined a practical compliance roadmap: "The first step for private equity or hedge fund investors in health care in Vermont will be to review their business and ensure that they are not influencing clinical operations, and that their documentation is clear." This advisory signals that due diligence on existing portfolios and prospective deal structures will become a material component of PE and hedge fund compliance frameworks in the health care sector.
The Vermont action is part of a coordinated state-level response to corporate consolidation in health care. California and Oregon have begun active enforcement of their own restrictions on corporate healthcare investors. Most notably, California's Attorney General Rob Bonta secured a $2.3 million settlement against Aspen Dental Management for alleged violations of the state's corporate-medicine ban, demonstrating that regulatory agencies are moving beyond legislation to enforcement and penalty collection.
This emerging regulatory landscape suggests that alternative investment firms with health care exposure should anticipate heightened compliance costs, longer deal timelines, and potential restrictions on operational control—factors that may alter return profiles and investment thesis viability for health care-focused funds.
The Vermont law, referenced as H.583, does not impose an outright prohibition on PE or hedge fund participation in health care investments. Instead, it establishes conditions and transparency requirements governing how such investors can structure their ownership stakes and operational involvement. Bergeron emphasized that the statute focuses on preventing investor influence over clinical operations—the core concern driving broader state legislative action in this area.
For alternative investment managers currently holding health care positions, Bergeron outlined a practical compliance roadmap: "The first step for private equity or hedge fund investors in health care in Vermont will be to review their business and ensure that they are not influencing clinical operations, and that their documentation is clear." This advisory signals that due diligence on existing portfolios and prospective deal structures will become a material component of PE and hedge fund compliance frameworks in the health care sector.
The Vermont action is part of a coordinated state-level response to corporate consolidation in health care. California and Oregon have begun active enforcement of their own restrictions on corporate healthcare investors. Most notably, California's Attorney General Rob Bonta secured a $2.3 million settlement against Aspen Dental Management for alleged violations of the state's corporate-medicine ban, demonstrating that regulatory agencies are moving beyond legislation to enforcement and penalty collection.
This emerging regulatory landscape suggests that alternative investment firms with health care exposure should anticipate heightened compliance costs, longer deal timelines, and potential restrictions on operational control—factors that may alter return profiles and investment thesis viability for health care-focused funds.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.